DK1944038T3 - Dengue-viruscapsidprotein, der inducerer et beskyttende respons og farmaceutisk sammensætning - Google Patents

Dengue-viruscapsidprotein, der inducerer et beskyttende respons og farmaceutisk sammensætning Download PDF

Info

Publication number
DK1944038T3
DK1944038T3 DK06791279.0T DK06791279T DK1944038T3 DK 1944038 T3 DK1944038 T3 DK 1944038T3 DK 06791279 T DK06791279 T DK 06791279T DK 1944038 T3 DK1944038 T3 DK 1944038T3
Authority
DK
Denmark
Prior art keywords
gly
lys
val
ala
asp
Prior art date
Application number
DK06791279.0T
Other languages
English (en)
Inventor
Vazquez Laura Lazo
Abarrategui Carlos Lopez
Vazquez Beatriz De La Caridad Sierra
Ramundo Susana Vazquez
Prado Iris Valdez
Cruz Lisset Hermida
Nieto Gerardo Enrique Guillen
Tirado Mara A Guadalupe Guzman
Morales Aa Da Zulueta
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of DK1944038T3 publication Critical patent/DK1944038T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (9)

1. Farmaceutisk præparat kendetegnet ved at være en vaccine, hvilken vaccine som immuniserende antigen indeholder capsidproteinet af en eller flere dengue-virus-serotyper i rekombinant form til anvendelse i en fremgangsmåde til induktion af et beskyttende immunrespons mod dengue-vira i den modtagende organisme ved immunforstærkning, hvor immunforstærkningen er den øgede induktion af antivirale serotype-specifikke antistoffer hos et individ ved hjælp af et heterologt dengue-antigen.
2. Farmaceutisk præparat ifølge krav 1 til anvendelse i en fremgangsmåde ifølge krav 1, hvor det heterologe dengue-antigen er domæne III af kappeproteinet af et dengue-virus.
3. Farmaceutisk præparat ifølge krav 1 til anvendelse i en fremgangsmåde ifølge krav 1, kendetegnet ved at det indeholder capsidproteinet af dengue-virus 1, 2, 3 eller 4, alene, blandet eller kombineret mellem hinanden.
4. Farmaceutisk præparat ifølge krav 1 til anvendelse i en fremgangsmåde ifølge krav 1 kendetegnet ved, at det indeholder capsidproteinet blandet eller kombineret med antigener, der er i stand til at inducere et humoralt og/eller cellulært respons.
5. Farmaceutisk præparat ifølge kravene 1-4 til anvendelse i en fremgangsmåde ifølge kravene 1-4 kendetegnet ved at det indeholder capsidproteinet blandet med et eller flere proteiner, der er identificeret i sekvenslisten som SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22 og SEQ ID NO: 23.
6. Farmaceutisk præparat ifølge kravene 1-5 til anvendelse i en fremgangsmåde ifølge krav 1-5 kendetegnet ved, at det indeholder capsidproteinet kemisk eller genetisk kondenseret til en eller flere sekvenser, der er identificeret i sekvenslisten som SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 og SEQ ID NO: 24.
7. Farmaceutisk præparat ifølge kravene 1 -6 til anvendelse i en fremgangsmåde ifølge et hvilket som helst af kravene 1-6 kendetegnet ved, at det indeholder capsidproteinet i aggregeret eller partikelform.
8. Farmaceutisk præparat ifølge kravene 1-7 til anvendelse i en fremgangsmåde ifølge et hvilket som helst af kravene 1-7 kendetegnet ved, at det indeholder et farmakologisk acceptabelt vehikel og et olieholdigt eller ikke olieholdigt hjælpestof.
9. Farmaceutisk præparat ifølge kravene 1-8 til anvendelse i en fremgangsmåde ifølge et hvilket som helst af kravene 1-8 kendetegnet ved, at det er et præventivt eller terapeutisk middel mod dengue-vira til oral, intramuskulær, subkutan, mukosal eller intravenøs anvendelse.
DK06791279.0T 2005-09-16 2006-09-18 Dengue-viruscapsidprotein, der inducerer et beskyttende respons og farmaceutisk sammensætning DK1944038T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20050168A CU23578A1 (es) 2005-09-16 2005-09-16 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
PCT/CU2006/000008 WO2007031034A1 (es) 2005-09-16 2006-09-18 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición farmacéutica

Publications (1)

Publication Number Publication Date
DK1944038T3 true DK1944038T3 (da) 2014-03-03

Family

ID=40132555

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06791279.0T DK1944038T3 (da) 2005-09-16 2006-09-18 Dengue-viruscapsidprotein, der inducerer et beskyttende respons og farmaceutisk sammensætning

Country Status (17)

Country Link
US (1) US7790173B2 (da)
EP (1) EP1944038B1 (da)
JP (1) JP5657204B2 (da)
KR (2) KR101350318B1 (da)
CN (1) CN101304760B (da)
AR (1) AR058049A1 (da)
AU (1) AU2006291863B2 (da)
BR (1) BRPI0616224B8 (da)
CA (1) CA2622827C (da)
CU (1) CU23578A1 (da)
DK (1) DK1944038T3 (da)
ES (1) ES2444691T3 (da)
MY (2) MY149395A (da)
PT (1) PT1944038E (da)
RU (1) RU2008114841A (da)
WO (1) WO2007031034A1 (da)
ZA (1) ZA200802740B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841785A2 (en) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CN104080475A (zh) * 2008-04-18 2014-10-01 法克斯因内特公司 鞭毛蛋白的缺失突变体以及使用方法
US20110150914A1 (en) * 2008-06-09 2011-06-23 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
EP2473624B1 (en) * 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
EP2723372A4 (en) * 2011-06-24 2015-03-04 Jolla Inst Allergy Immunolog PROTECTION AGAINST DENGUE VIRUS AND PREVENTION AGAINST HEAVY DENGUE ILLNESSES
BR112015007606A2 (pt) 2012-10-04 2018-01-30 Univ Leland Stanford Junior métodos e reagentes para a detecção, quantificação e serotipagem de vírus da dengue
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
US10487120B2 (en) * 2015-02-09 2019-11-26 Academia Sinica Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018169550A1 (en) * 2017-03-17 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time rt-pcr assay for detection of dengue, chikungunya, and zika viruses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ES2254055T3 (es) 1991-09-19 2006-06-16 The United States Of America, As Represented By The Secretary, Departm. Of Health And Human Services Flavivirus quimericos y/o de crecimiento restringido.
DE69624815T2 (de) * 1995-05-24 2003-07-10 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
EP0907659A1 (en) 1996-05-10 1999-04-14 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
CU22666A1 (es) 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
CU22683A1 (es) 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
ATE291032T1 (de) 1997-08-11 2005-04-15 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide
ATE314476T1 (de) * 1997-10-08 2006-01-15 Us Gov Health & Human Serv Chimärer impfstoff gegen das zeckenenzephalitis virus
EP1185691B1 (en) 1999-04-30 2009-04-29 Novartis Vaccines and Diagnostics, Inc. Neisseria genomic sequences and methods of their use
CA3060687C (en) * 2001-05-22 2021-05-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
US20040213808A1 (en) 2002-12-11 2004-10-28 Michael Lieberman Recombinant vaccine against flavivirus infection
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
EP1841785A2 (en) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.

Also Published As

Publication number Publication date
US7790173B2 (en) 2010-09-07
PT1944038E (pt) 2014-02-21
ZA200802740B (en) 2008-12-31
KR20130100026A (ko) 2013-09-06
BRPI0616224B8 (pt) 2021-05-25
EP1944038B1 (en) 2013-11-27
CA2622827C (en) 2015-12-15
US20080311157A1 (en) 2008-12-18
BRPI0616224A2 (pt) 2013-02-19
CU23578A1 (es) 2010-09-30
CN101304760B (zh) 2013-03-13
CN101304760A (zh) 2008-11-12
AU2006291863B2 (en) 2012-09-20
WO2007031034A1 (es) 2007-03-22
EP1944038A1 (en) 2008-07-16
BRPI0616224B1 (pt) 2019-01-15
AU2006291863A1 (en) 2007-03-22
KR101350318B1 (ko) 2014-01-14
JP5657204B2 (ja) 2015-01-21
JP2009507864A (ja) 2009-02-26
MY161452A (en) 2017-04-14
CA2622827A1 (en) 2007-03-22
ES2444691T3 (es) 2014-02-26
MY149395A (en) 2013-08-30
KR20080048068A (ko) 2008-05-30
RU2008114841A (ru) 2009-10-27
AR058049A1 (es) 2008-01-23

Similar Documents

Publication Publication Date Title
DK1944038T3 (da) Dengue-viruscapsidprotein, der inducerer et beskyttende respons og farmaceutisk sammensætning
RU2209082C2 (ru) Химерные флавивирусные вакцины
Apt et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen
US8029802B2 (en) Vaccines against Japanese encephalitis virus and West Nile virus
KR101150584B1 (ko) 웨스트 나일 바이러스 백신
EP0604566A1 (en) Chimeric and/or growth-restricted flaviviruses
US20180228887A1 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
Eckels et al. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines
KR100991717B1 (ko) 바이러스에 대한 효과를 유도하는 단백질을 코딩하는키메라 사슬
CA2235334A1 (fr) Vaccin polyvalent anti-dengue
Schlesinger et al. New approaches to flavivirus vaccine development